Melanocortin Receptor 4 - Pipeline Review, H2 2020
Summary
Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 - Pipeline Review, H2 2020, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 2 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Genetic Disorders, Musculoskeletal Disorders, Central Nervous System, Genito Urinary System And Sex Hormones and Immunology which include indications Obesity, Type 2 Diabetes, Cachexia, Gouty Arthritis (Gout), IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis, Prader-Willi Syndrome (PWS), Rheumatoid Arthritis and Smith-Magenis Syndrome (Chromosome 17p11.2 Deletion Syndrome). Furthermore, this report also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope- The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
- The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics
Reasons to Buy- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Introduction
- Global Markets Direct Report Coverage
- Melanocortin Receptor 4 (MC4R) - Overview
- Melanocortin Receptor 4 (MC4R) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
- Aequus BioPharma Inc
- Eton Pharmaceuticals Inc
- LG Chem Ltd
- Mallinckrodt Plc
- Palatin Technologies Inc
- Rhythm Pharmaceuticals Inc
- Melanocortin Receptor 4 (MC4R) - Drug Profiles
- (liraglutide + setmelanotide hydrochloride) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AQB-565 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- bremelanotide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- corticotropin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- corticotropin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- LB-54640 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- LR-19021 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PL-8905 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PL-9610 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- setmelanotide hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- setmelanotide hydrochloride ER - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Agonize MC4-R for Obesity - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Melanocortin Receptor 4 (MC4R) - Dormant Products
- Melanocortin Receptor 4 (MC4R) - Discontinued Products
- Melanocortin Receptor 4 (MC4R) - Product Development Milestones
- Featured News & Press Releases
- Oct 20, 2020: City of Rockford $10 billion lawsuit against pharmaceutical giant Mallinckrodt threatened by bankruptcy
- Sep 28, 2020: LG Chem's obesity treatment wins ODD status in US
- Jul 16, 2020: Rhythm Pharmaceuticals announces publication of results from phase 2 study of Setmelanotide in Bardet-Biedl Syndrome in diabetes, obesity and metabolism
- Jul 06, 2020: MC4R agonist (LB54640) Poster Presentation at ADA 2020
- Jul 01, 2020: Rhythm Pharmaceuticals announces submission of Marketing Authorization Application to the European Medicines Agency for setmelanotide in POMC and LEPR deficiency obesities
- Jul 01, 2020: Rhythm Pharmaceuticals receives rare pediatric disease designation from U.S. Food and Drug Administration for setmelanotide for treatment of POMC and LEPR deficiency obesities
- Jun 24, 2020: Positive results from Phase 2 study of once-weekly FluidCrystal formulation of setmelanotide in healthy volunteers with obesity
- Jun 24, 2020: Rhythm Pharmaceuticals announces positive results from phase 2 study of once-weekly formulation of setmelanotide in healthy obese volunteers
- Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
- Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
- Jun 01, 2020: Mallinckrodt will appeal District Court ruling in case involving ongoing Acthar medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
- Jun 01, 2020: LG Chem Life Sciences Company receives FDA approval for IND application of LB54640 for the treatment of genetic disorders of obesity
- May 13, 2020: Rhythm Pharmaceuticals announces FDA acceptance of new drug application for Setmelanotide for the treatment of POMC and LEPR deficiency obesities
- Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4 study in rheumatoid arthritis (RA) in Rheumatology and Therapy
- Mar 30, 2020: Rhythm Pharmaceuticals completes rolling submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR deficiency obesities
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development by Stage of Development, H2 2020
- Number of Products under Development by Therapy Areas, H2 2020
- Number of Products under Development by Indication, H2 2020
- Number of Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Investigation by Universities/Institutes, H2 2020
- Products under Investigation by Universities/Institutes, H2 2020
- Number of Products by Stage and Mechanism of Actions, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Pipeline by Aequus BioPharma Inc, H2 2020
- Pipeline by Eton Pharmaceuticals Inc, H2 2020
- Pipeline by LG Chem Ltd, H2 2020
- Pipeline by Mallinckrodt Plc, H2 2020
- Pipeline by Palatin Technologies Inc, H2 2020
- Pipeline by Rhythm Pharmaceuticals Inc, H2 2020
- Dormant Products, H2 2020
- Dormant Products, H2 2020 (Contd..1), H2 2020
- Discontinued Products, H2 2020
- List of Figures
- Number of Products under Development by Stage of Development, H2 2020
- Number of Products under Development by Therapy Areas, H2 2020
- Number of Products under Development by Top 10 Indications, H2 2020
- Number of Products by Mechanism of Actions, H2 2020
- Number of Products by Stage and Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020